Laboratorios Farmaceuticos ROVI (ROVI.MC) Azione Prezzo
Laboratorios Farmaceuticos ROVI Prezzo
Il fatturato è cresciuto a un tasso composto del 12,6% annuo negli ultimi 19 anni, raggiungendo 743,48 Mio. EUR. L'utile per azione è cresciuto del 19,0% all'anno negli ultimi 19 anni. Il margine netto di Laboratorios Farmaceuticos ROVI si attesta al 18,9%, in calo rispetto al 23,6% di alcuni anni fa. Laboratorios Farmaceuticos ROVI offre attualmente un rendimento da dividendo di circa il 1,60%. Il payout ratio è pari a circa il 34% degli utili. Il dividendo è cresciuto del 15,7% all'anno negli ultimi 17 anni. Gli analisti fissano un target di prezzo mediano di 85,07 EUR, ovvero il 45,9% sopra il prezzo attuale. Su 16 analisti, 13 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Laboratorios Farmaceuticos ROVI Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Laboratorios Farmaceuticos ROVI Azione e analisi azionaria
Domande frequenti sull'azione Laboratorios Farmaceuticos ROVI
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Gli analisti fissano attualmente un prezzo obiettivo medio di 84,26 EUR per l’azione Laboratorios Farmaceuticos ROVI (mediana: 85,07 EUR), pari a +44,5 % rispetto all’ultimo prezzo. Il consenso si basa su 16 giudizi di analisti.
Laboratorios Farmaceuticos ROVI Prezzi Obiettivo Analisti 2026
16 analisti valutano attualmente l’azione Laboratorios Farmaceuticos ROVI: 13 raccomandano l’acquisto, 3 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Laboratorios Farmaceuticos ROVI ricavi pari a 774,25 Mio. EUR e un utile per azione di 2,79 EUR.
Laboratorios Farmaceuticos ROVI Prezzi Obiettivo Analisti 2026
L’azione Laboratorios Farmaceuticos ROVI (ROVI.MC) è quotata su 9 borse, tra cui: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
Il attesa fatturato di Laboratorios Farmaceuticos ROVI ammonta a 774,25 Mio. EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Laboratorios Farmaceuticos ROVI ammonta a 142,61 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Laboratorios Farmaceuticos ROVI è attualmente 20,91. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Laboratorios Farmaceuticos ROVI.
Il rapporto prezzo/fatturato (P/S) di Laboratorios Farmaceuticos ROVI è attualmente 3,85. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Laboratorios Farmaceuticos ROVI.
Il Quality Score AlleAktien per Laboratorios Farmaceuticos ROVI è 6/10.
L'ISIN di Laboratorios Farmaceuticos ROVI è ES0157261019. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Laboratorios Farmaceuticos ROVI è A0M0GQ. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Laboratorios Farmaceuticos ROVI è ROVI.MC. Con questo simbolo di borsa vengono negoziate le azioni Laboratorios Farmaceuticos ROVI in borsa.
Azione Laboratorios Farmaceuticos ROVI
Gruppo di pari di Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
Altre metriche e analisi di Laboratorios Farmaceuticos ROVI in Deep Dive.
La nostra analisi azionaria dell'azione Laboratorios Farmaceuticos ROVI include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Laboratorios Farmaceuticos ROVI. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: